MedTrace Logo

Phase II Study of Fruquintinib Combined With Sintilimab and TACE for Inoperable Primary Hepatocellular Carcinoma

NCT05971199 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2023-08-02

No results posted yet for this study

Summary

The goal of this prospective, interventional clinical trial is to evaluation of fruquintinib in combination with sintulimab and TACE for inoperable primary hepatocellular carcinoma for progression-free survival (PFS).

Conditions

Interventions

DRUG

Fruquintinib

Fruquintinib:5 mg capsule orally once daily on day 1-21 in 28-day cycles；

DRUG

Sintilimab

Sintilimab: 200 mg i.v. every 3 weeks

DEVICE

Transcatheter arterial chemoembolization（TACE）

Transcatheter arterial chemoembolization（TACE）

Sponsors & Collaborators

  • Zhejiang Cancer Hospital

    lead OTHER

Principal Investigators

  • Guoliang Shao · Zhejiang Cancer Hospital Hangzhou, Zhejiang, China

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-23
Primary Completion
2024-12-23
Completion
2024-12-23

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05971199 on ClinicalTrials.gov